
	April 4, 2026						January 3, 2026
(in millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Intangible assets subject to amortization:
Patents	$	47.2	$	(20.4)	$	26.8	$	46.6	$	(19.8)	$	26.8
Customer relationships	24.6		(14.9)		9.7		24.6		(14.7)		9.9
Acquired technologies	28.5		(21.0)		7.5		28.6		(20.7)		7.9
Trademarks	13.9		(9.3)		4.6		14.0		(9.2)		4.8

Licenses	2.3		(1.8)		0.5		2.3		(1.6)		0.7
Licenses-related party	7.5		(7.4)		0.1		7.5		(7.4)		0.1
Other	6.6		(4.8)		1.8		6.6		(4.7)		1.9
Total intangible assets subject to amortization, net	$	130.6	$	(79.6)	$	51.0	$	130.2	$	(78.1)	$	52.1

Finite lived intangible assets have a weighted-average amortization period ranging from eleven years to fourteen years. Total amortization expense for the three months ended April 4, 2026 and March 29, 2025 was $1.9 million and $2.1 million, respectively.

Total renewal costs capitalized for patents and trademarks for the three months ended April 4, 2026 and March 29, 2025 were $0.3 million and $0.2 million, respectively. As of April 4, 2026, the weighted-average number of years until the next renewal was two years for patents and six years for trademarks.

Indefinite-lived intangible assets are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist. For goodwill, the Company performs a qualitative assessment during the fourth quarter each year, for its annual impairment analysis. In the fourth quarter of 2025, the Company performed its annual impairment analysis, and concluded that it was more likely than not that the fair value of the healthcare reporting unit was greater than its carrying value. Accordingly, no further testing was required on this reporting unit.